by Steve Oconnor | May 14, 2020 | Shift News Updates
Shift’s E1V1.11 drug compound to treat Spinal Muscular Atrophy (SMA) granted Orphan Drug Status by FDA. Overland Park: The Food and Drug Administration (FDA) granted orphan drug designation for Shift Pharmaceutical’s lead drug compound to treat all forms of spinal...
by Steve Oconnor | Apr 18, 2020 | Shift News Updates
CMT Research Foundation funds Shift to explore novel series of drugs created to control the expression of PMP22 gene Overland Park: In late January, the CMT Research Foundation (CMTRF) announced a partnership with Shift Pharmaceuticals to further research in...
by Steve Oconnor | May 19, 2019 | Shift News Updates
Overland Park: Shift Pharmaceuticals is pleased to announce the Company has been awarded a grant through the Congressional Directed Medical Research Program (CDMRP) to further the development of their initial drug candidate (E1v1.11) for the treatment of Spinal...
